ACIUAC Immune SA

CSNasdaq (XNAS)·USD

Identity

Security key: 11246
Ticker: ACIU
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2016-09-23
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: ACIU

Detail

Enriched 2026-08-14 20:47

Market cap: $266,646,761.26
Shares outstanding (class): 101,773,573
Shares outstanding (weighted): 101,773,573
SIC: —
Employees: 122
Location: —
Homepage: https://www.acimmune.com
Description: AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Market cap and share counts drift.

Funds holding this security

3 funds · 3 positions · $1.25M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
iShares Biotechnology ETF iShares Trust	IBB	$1.22M	0.02%	443,438 NS	TICKER
JNL/DFA U.S. Small Cap Fund JNL Series Trust	—	$21.9K	0.00%	7,966 NS	TICKER
AST Small-Cap Equity Portfolio Advanced Series Trust	—	$11.9K	0.00%	4,330 NS	TICKER

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

This match is a candidate, not a mapping. N-PORT tickers are filer-entered free text and collide with delisted and foreign symbols. Only 13% of positions carry a ticker at all. Good enough to ask which funds report holding a symbol; not good enough to build exposure reporting on. Prefer the ISIN-resolved link, which is marked FIGI_COMPOSITE.

Funds holding this security

Identifiers

master.security_identifier

TICKERACIU
CIK0001651625
ISINCH0329023102
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: AC Immune SA is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, fitting the biotechnology industry.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.